We analysed serum samples of 209 subjects immunized with yellow fever vaccine 17D by different assays: neutralization test, immunofluorescence assay, haemagglutination inhibition test and ELISA, for presence of 17D-specific antibodies. Serum samples were taken from a few weeks up to 35 years after vaccination. The neutralization test had the highest sensitivity. There was no correlation of results between the serological assays. Considering NT titres Ͼ 1:10 as indicating protection, we found that about 75% of subjects remained immune even 10 years after vaccination, with a median NT titre of 1:40 in reactive sera.
Introduction
The live attenuated 17D vaccine strain against yellow fever (YF) virus infection introduced by Theiler in 1937 (Theiler & Smith 1937 ) is an effective and well-tolerated vaccine. As a manufacturer of YF vaccine we are frequently confronted with questions regarding protective immunity after 17D vaccination. However, since most of the currently licensed vaccines depend on the presence of neutralizing antibodies to control wild-type infections, we looked for specific anti17D antibodies and neutralizing antibodies against the 17D vaccine strain. To evaluate the immune response in different serological assays measuring humoral immune response and to determine reliable parameters for the status of YF vaccinees, we collected sera of YF vaccinees with a welldocumented medical record up to 38 years after vaccination. Most sera were analysed in parallel by neutralization test (NT), immunofluorescence test (IFT), haemagglutination inhibition test (HIT) and in ELISA for YF-specific IgG antibodies. Analysis of the serological YF immune response in different assays is useful for the methodology of investigating the antibody response and defining serological parameters correlating with vaccine efficacy.
Material and methods
The live attenuated 17D YF vaccine used for vaccination of study subjects came from four manufacturers: 153 individuals were vaccinated with 17D produced at the Robert KochInstitut (Germany), 39 received vaccine from Glaxo-Wellcome (UK), 4 were given Stamaril ® (from Pasteur, and one person was vaccinated with Connaught 17D vaccine (Canada). Thirteen subjects had received 17D vaccines of unknown origin. The 209 participants with a vaccination record who were included in this study ranged in age from 10 to 79 years; 25% were women. At the time of sampling, the age distribution of 158 persons was: age 10-20, n ϭ 27; age 21-30, n ϭ 32; age 31-40, n ϭ 39; age 41-50, n ϭ 34 persons; age 51-60, n ϭ 21; age 61-79, n ϭ 5. The remaining 51 samples were provided by physicians without age data. Most vaccinees had a known TMIH496 vaccination history concerning other flavivirus vaccines such as TBE and/or JEV and known risk of acquired dengue infection after staying in endemic areas. Serum samples were collected from patients during routine hospital investigations and from vaccinees before a second vaccination at the Clinic for Internal Medicine, Rostock and at the Robert-KochInstitute, Berlin. All patients gave informed written consent. The ethics committee of The University of Rostock approved the study. Sera were stored at -20 ЊC until use.
Neutralization test
A plaque reduction assay first described by De Madrid & Porterfield (1969) was used as neutralization test (NT). It was slightly modified and performed as described by Reinhardt et al. (1998) . Briefly, PS-cells at a concentration of 3-4 ϫ 10 5 /ml were seeded into 24-well plates (Nunc, Denmark) at a volume of 0.5 ml/well. Cells were cultured in Leibovitz medium (L-15, Gibco BRL, Germany) overnight at 37 ЊC and washed once with L-15 medium supplemented with 5% FCS before adding 0.3 ml of a 1:5 dilution of the test sera. All sera were assayed four in parallel in two-fold dilutions ranging from 1:10 to 1:320 for the final dilutions. The sera were mixed with approximately 100 tissue culture infectivity doses of the reference 17D virus preparation used in our laboratory (lot number: 354/1). After 1 h of incubation at 37 ЊC, 0.2 ml of this mixture was added to an equal volume of PS-cells at a density of 6 ϫ 10 5 cells/ml. A 1.6% methylcellulose/L-15 solution (BDH Chemicals Ltd, UK) supplemented with 3% FCS was overlaid after 4 h of incubation. Cultures were incubated for 5 days at 37 ЊC. Thereafter cells were washed with PBS and fixed with 10% formaldehyde solution for 10 min. Naphthalene black was used for staining cell layers, plaques were counted and the 90% neutralization titres calculated. NT titres Ͻ 1:10 were considered negative. Titres of 1:10 were interpreted as borderline.
Immunofluorescence assay
For preparation of the immunofluorescence assay (IF), 17D-infected PS-cells were grown for 2 days on glass slides with 10 marked rings of 20 l volume (Hölzel, Germany) at a density of 5 ϫ 10 5 /ml. Uninfected PS-cells were used as negative controls. After incubation at 37 ЊC, cells were fixed for 30 min in icecold acetone (Merck, Germany) and stored at Ϫ20 ЊC. Slides were thawed at room temperature immediately before use. Sera were diluted twofold with PBS supplemented with 2% bovine serum albumin (BSA, Sigma, Germany) starting at a concentration of 1:10 before adding 20 l of diluted serum per ring. The slides were incubated in a humid chamber for 1 h at 37 ЊC and then washed three times with PBS and once with distilled water. After air-drying of the slides, 15 l of a dilution of a FITC-conjugated anti-human IgG antibody (Medac, Germany) were added per ring. The slides were incubated for 1 h at 37 ЊC, then washed three times in PBS and evaluated using a fluorescence microscope (Zeiss, Germany). As a negative control the uninfected PS-cells on each slide were covered with 20 l of dilution (1:10-1:640) of the respective serum. As a positive control an in-house human reference serum was included on every slide. IF titres of 1:10 were considered nonspecific negative.
ELISA
For coating ELISA plates, 17D vaccine was diluted in carbonate-buffer (pH 7.0) and incubated at 4 ЊC for 12 h. After washing with phosphate-buffered saline pH 7.0 (PBS), plates were incubated with blocking buffer (PBS ϩ 1% BSA) for 1 h. Serum samples diluted with PBS from 1:100 to 1:12 800 were incubated for 1 h at 37 ЊC, then washed 3 times with washing buffer (PBS ϩ 0.1% Tween 20), and incubated for another hour with an anti-human IgG antibody coupled to peroxidase (Dianova, Germany), washed again 3 times and developed using OPD as substrate. Absorption was measured in an ELISA reader (Dynatech) at 490 nm. Absorption values twice as high as those of the negative control (PBS) were considered positive. ELISA titres Յ 1:100 were considered negative. A human reference serum as an in-house positive control was included on every plate.
Haemagglutination inhibition test
The haemagglutination inhibition test (HIT) was performed according to standard procedures (Shope & Sather 1979) . Briefly, YF 17D was propagated in suckling mice. Virus was recovered from mouse brain with acetone-sucrose extraction. Virus antigen titres were determined by haemagglutination of goose erythrocytes. The sera were free from inhibitors as assessed by repeated acetone treatment and tested in serial dilutions from 1:10 to 1:80 against 8 units of haemagglutination antigen.
Results
Over three years a total of 209 subjects were included in this study. Serum samples were collected and analysed in the different assays. Post-vaccination NT values clearly show a time-dependent decrease (Figure 1 ). In the overall trend calculation, the NT titre levels at about 1:20 for all sera analysed within this time frame. A more detailed analysis of NT results, especially for the first decade after YF vaccination, is shown in Table 1 . These are of high interest, since WHO recommends YF vaccination every 10 years for people at risk (WHO 1997) . The percentage of reactive sera with an NT titre Ͼ 1:10 clearly shows a decrease from 94% significant positive results in the first year to 74.5% after 10 years. This decrease is reflected by a median titre of 1:70 in the first year and 1:40 after 10 years for reactive sera. There was no consistent correlation between NT results and the other assays (Table 2) . Dividing NT results into three groups of high, medium and no neutralizing activity, there is no correlation with respective results obtained by IFT. At all three levels the majority of sera (52.1% -67.7%) did not react in IF, revealing the remarkably low sensitivity of this assay. Only in sera with NT titres over 1:50 we observed a slight increase of the IF titres to 42.3%. ELISA results show high sensitivity but no significant correlation with NT results.
Discussion
We analysed the humoral immune response directed against 17D YF after vaccination over long periods of time. Comparing four serological tests demonstrated that neither IFT nor ELISA and HIT are reliable serological tests. IFT, which is highly specific and permits identification of nonspecific reactions, appeared extremely low in sensitivity compared to the NT. Its low sensitivity was probably caused by the small test volume used. By contrast, the ELISA shows high sensitivity but is hampered by nonspecific reactions, a common problem in flavivirus diagnostics (Yoshida et al. 1992) . The sera examined in the HIT showed no or minimal titres which is in accordance with previous results demonstrating only minimal titres and an increase of HI antibodies over time after vaccination (Groot & Ribeiro 1962) . The NT seems to give the most reliable results in assessing virus neutralizing antibodies, (Smithburn & Mahaffy 1945; Groot & Ribeiro 1962; Wisseman & Sweet 1962; Rosenzweig et al. 1963) . Another study also using the plaque reduction assay to determine neutralizing capacity does not give a clear description of the method used and lacked complete medical records of the vaccinees (Poland et al. 1981) . The results of our comparative study corroborate earlier data and clearly show the superiority of the plaque reduction assay. We therefore advocate the NT as the appropriate tool to assess successful vaccination. In Figure 1 , the calculated trend for the NT titre for all 209 sera 10-20 years after vaccination was 1:30-1:20, which seems to signify protection. From previous studies we can speculate that vaccinees without detectable NT titres may also be properly protected because there is a cell-mediated protective effect, although of unclear efficacy (Reinhardt et al. 1998) . The involvement of cytotoxic T-cells in defending virus infections is a well-known phenomenon but the relative contributions of humoral and cellular mediated immunity for protection remain unclear Oehen et al. 1992) . The capacity to activate the cellular immune system and induce T-cell memory are important mechanisms of protection from wild-type infection, since frequently T-cells are recognizing more conserved epitopes that do not change due to antibody-mediated selective pressure (Hill et al. 1992) .
Therefore the question whether the increasing number of NT negative subjects from 6% in the first year to 25.5% 11-38 years postvaccination are protected by cellular immunity requires further investigation. In general, the increase of NT-negative subjects agrees with the findings of Poland et al. (1981) describing 21.6% nonreactive sera in NT 30-35 years post vaccination. Whether the 6% of subjects without reactivity for 17D vaccine in NT in our study also fail to establish cellular immunity remains unclear. Overall we did observe 81.5% significantly reactive sera in the first decade with a median NT titre of 1:40 in reactive subjects (Table 1) . We can assume that this long-lasting persistence of reactive antibodies depends on a permanent trigger of the immune system as proposed by Gray & Matzinger (1991) and Hill et al. (1992) . The relative contributions of cellular and humoral immunity mediating protection against YF infection are not known. So far our data indicate that NT results are the most appropriate parameters for monitoring 17D vaccine efficacy.
